Methotrexate, Cyclosporine A, and Biologics Protect against Atherosclerosis in Rheumatoid Arthritis
| Autor: | Romana Bogusławska-Walecka, Witold Tłustochowicz, Robert Kruszewski, Krzysztof Kłos, Bartłomiej Kisiel, Krzysztof Duda, Aleksandra Juszkiewicz, Jadwiga Staniszewska-Varga, Małgorzata Tłustochowicz, Artur Bachta, Anna Raczkiewicz, Rafał Płoski |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
musculoskeletal diseases Male medicine.medical_specialty Article Subject Immunology Arthritis Disease Pharmacology Gastroenterology Carotid Intima-Media Thickness Severity of Illness Index Arthritis Rheumatoid Internal medicine Severity of illness medicine Prevalence Immunology and Allergy Humans cardiovascular diseases skin and connective tissue diseases Biological Products business.industry Case-control study General Medicine Middle Aged medicine.disease Atherosclerosis Antirheumatic Agents Methotrexate Intima-media thickness Rheumatoid arthritis Case-Control Studies cardiovascular system Cyclosporine Disease Progression Clinical Study Female lcsh:RC581-607 business medicine.drug |
| Zdroj: | Journal of Immunology Research Journal of Immunology Research, Vol 2015 (2015) |
| ISSN: | 2314-7156 |
| Popis: | Introduction. The risk of cardiovascular disease is increased in rheumatoid arthritis (RA). A meta-analysis showed increased intima media thickness (IMT) in RA. It has been shown that disease modifying antirheumatic drugs (DMARDs) may influence the progression of atherosclerosis. However, it was suggested that biologics may be more efficient than other DMARDs (including methotrexate—MTX) in protecting against atherosclerosis.Objectives. The aim of this study was to assess the influence of different RA characteristics and treatment regimens on IMT and atherosclerotic plaques.Patients and Methods. 317 RA patients and 111 controls were included in the study. IMT was measured in carotid (CIMT) and femoral (FIMT) arteries. Arteries were screened for the presence of plaques.Results. CIMT, FIMT, and prevalence of plaques were lower in patients treated with methotrexate (MTX) ≥ 20 mg/wk, cyclosporine (CsA), or biologics than in patients treated with lower doses of MTX and other disease modifying antirheumatic drugs. No differences in IMT between patients treated with MTX ≥ 20 mg/wk, biologics, or CsA were found.Conclusions. We found a beneficial effect of MTX ≥ 20 mg/wk, biologics, and CsA on atherosclerosis. We do not confirm a stronger influence of biologics on IMT compared with therapeutic doses of MTX. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text